Check Cap Ltd

Healthcare US CHEK

NoneUSD
0.00(0%)

Last update at 2026-04-30T21:06:27.595843Z

Day Range

LowHigh

52 Week Range

0.59186.00

LowHigh

Fundamentals

Previous Close -
Market Cap9.42M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA-9.30100M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-4.3

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-25.14900M	-25.14900M	-17.56800M	-19.10800M	-17.20200M
Minority interest	-	-	-	-	-
Net income	-25.14900M	-25.14900M	-17.56800M	-19.25400M	-17.09200M
Selling general administrative	9.46M	9.30M	9.55M	5.76M	4.97M
Selling and marketing expenses	-	-	0.09M	-	-
Gross profit	-0.16100M	-	-0.21200M	-	-
Reconciled depreciation	-	0.16M	0.34M	0.40M	0.20M
Ebit	-9.46200M	-	-17.86100M	-20.03400M	-17.32100M
Ebitda	-9.30100M	-	-17.64900M	-19.63000M	-17.11600M
Depreciation and amortization	0.16M	-	0.21M	0.40M	0.20M
Non operating income net other	-	-	-	-	-
Operating income	-25.94900M	-9.46200M	-19.28700M	-20.03400M	-17.32100M
Other operating expenses	25.95M	-	17.86M	20.03M	17.32M
Interest expense	0.00900M	0.00900M	0.01M	0.01M	0.01M
Tax provision	-	-	-	-	-
Interest income	-	0.81M	1.92M	0.93M	0.10M
Net interest income	-	0.80M	1.90M	0.93M	0.11M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	-0.00000M	0.15M	-0.11000M
Total revenue	-	0.00000M	0.00000M	0.00000M	0.00000M
Total operating expenses	25.95M	9.46M	17.65M	20.03M	17.32M
Cost of revenue	0.16M	-	0.21M	-	-
Total other income expense net	0.80M	-16.48700M	0.29M	0.93M	0.12M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-	-25.14900M	-17.62300M	-19.10800M	-17.20200M
Net income applicable to common shares	-	-	-	-19.10800M	-17.20200M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	0.38M	0.38M	25.02M	45.44M	55.66M
Intangible assets	-	-	-	-	-
Earning assets	-	-	-	-	-
Other current assets	-	-	0.06M	0.58M	0.84M
Total liab	1.83M	1.83M	1.33M	4.13M	4.97M
Total stockholder equity	-1.45000M	-1.45000M	23.69M	41.31M	50.69M
Deferred long term liab	-	-	-	-	-
Other current liab	1.20M	-	1.19M	2.12M	2.64M
Common stock	83.75M	-	83.75M	83.66M	68.79M
Capital stock	-	83.75M	83.75M	83.66M	68.79M
Retained earnings	-170.01000M	-170.01000M	-144.86100M	-127.29300M	-108.18500M
Other liab	-	-	-	0.09M	0.13M
Good will	-	-	-	-	-
Other assets	-	-	0.00000M	-	-
Cash	-	0.00000M	24.76M	4.09M	26.46M
Cash and equivalents	-	-	-	-	-
Total current liabilities	1.81M	1.81M	1.33M	3.41M	4.04M
Current deferred revenue	-	-	-	-	-
Net debt	0.14M	-	-24.75600M	-3.12600M	-25.31200M
Short term debt	0.12M	-	-	0.34M	0.35M
Short long term debt	-	-	-	-	-
Short long term debt total	0.14M	-	-	0.96M	1.15M
Other stockholder equity	84.81M	-	84.80M	84.94M	90.09M
Property plant equipment	-	-	-	2.81M	2.91M
Total current assets	0.27M	0.27M	24.86M	42.63M	52.75M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	41.31M	50.69M
Short term investments	0.27M	0.27M	15.91M	37.61M	25.10M
Net receivables	-	-	0.04M	0.09M	0.21M
Long term debt	-	-	-	-	-
Inventory	-	-	-	-	-
Accounts payable	0.49M	0.49M	0.14M	0.95M	1.05M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	-	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-	-0.00000M	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.11M	0.11M	0.16M	2.81M	2.91M
Capital lease obligations	-	0.14M	0.00000M	0.96M	1.15M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	15.65M	11.37M	-12.50800M	-16.00600M
Change to liabilities	-	-	-	0.21M	0.36M
Total cashflows from investing activities	-0.00084M	-	21.36M	-12.50800M	-16.00600M
Net borrowings	-	-	-	-	-
Total cash from financing activities	-	0.00000M	0.00000M	8.85M	51.02M
Change to operating activities	-	-	-	-0.46500M	-0.12000M
Net income	-25.14900M	-25.14900M	-17.56800M	-19.10800M	-17.20200M
Change in cash	-0.00884M	-8.84400M	4.40M	-22.36500M	18.75M
Begin period cash flow	8.84M	8.84M	4.44M	26.81M	8.05M
End period cash flow	-	8.84M	8.84M	4.44M	26.81M
Total cash from operating activities	-0.00800M	-8.00400M	-16.95400M	-18.70700M	-16.26400M
Issuance of capital stock	-	0.00000M	0.00000M	8.85M	31.80M
Depreciation	0.16M	0.16M	0.21M	0.40M	0.20M
Other cashflows from investing activities	-0.00084M	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	-	-	-	-
Change to account receivables	-	-	-	-	-
Sale purchase of stock	-	-	-	-	0.00000M
Other cashflows from financing activities	-	-	21.36M	-12.50800M	19.22M
Change to netincome	-	-	-	0.26M	0.49M
Capital expenditures	0.00000M	0.00000M	0.08M	0.49M	1.01M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-0.00001M	0.48M	-1.27200M	-0.25800M	0.24M
Stock based compensation	0.01M	0.01M	-0.05700M	0.88M	0.49M
Other non cash items	24.97M	-	1.73M	-0.62400M	-
Free cash flow	-0.00800M	-8.00400M	-17.03700M	-19.19300M	-17.27000M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to EBITDA (x)
CHEK Check Cap Ltd	- -%	-	-	-	-	3.38	0.74
TMO Thermo Fisher Scientific Inc	-8.13 1.69%	473.95	34.71	23.87	4.62	4.43	5.29	20.89
DHR Danaher Corporation	1.97 1.12%	178.08	29.09	28.01	5.67	3.20	6.00	19.09
A Agilent Technologies Inc	2.35 1.74%	137.40	34.36	26.39	6.59	7.14	6.78	23.56
IDXX IDEXX Laboratories Inc	9.91 1.80%	560.73	49.99	45.66	11.29	27.85	11.46	34.46

Reports Covered

View All

Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.

Check Cap Ltd

29 Abba Hushi Ave., Isfiya, Israel, 3009000

972 4 830 3401
https://check-cap.com

Key Executives

Name	Title	Year Born
Mr. Alex Ovadia	CEO & Director	1962
Dr. Yoav Kimchy Ph.D.	Founder & Chief Technology Officer	1961
Ms. Mira Rosenzweig	Chief Financial Officer	1972
Mr. Joshua Belkar	VP of Operations	1969
Ms. Noa Reshef M.B.A.	Director of HR	NA
Dr. Yoav Kimchy Ph.D.	Founder & Interim CTO	1961
Mr. Joshua Belkar	Vice President of Operations	1969
Ms. Iris Even-Tov	Interim Chief Financial Officer	NA
Ms. Noa Reshef M.B.A.	Director of Human Resources	NA
Mr. David Lontini	Interim CEO & Chairman of the Board	1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.